Cargando…

Effect of sorafenib starting dose and dose intensity on survival in patients with hepatocellular carcinoma: Results from a Canadian Multicenter Database

BACKGROUND: Sorafenib has been shown to improve survival in patients with advanced hepatocellular carcinoma (HCC), however, full dose can be difficult to tolerate. The aim of this study was to determine whether sorafenib starting dose and mean dose intensity affect survival. METHODS: Patients treate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alghamdi, Mohammed A., Amaro, Carla P., Lee‐Ying, Richard, Sim, Hao‐Wen, Samwi, Haider, Chan, Kelvin K., Knox, Jennifer J., Ko, Yoo‐Joung, Swiha, Mina, Batuyong, Eugene, Romagnino, Adriana, Cheung, Winson Y., Tam, Vincent C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7367626/ https://www.ncbi.nlm.nih.gov/pubmed/32529797 http://dx.doi.org/10.1002/cam4.3228

Ejemplares similares

Prognosis of patients with hepatocellular carcinoma treated with sorafenib: a comparison of five models in a large Canadian database
por: Samawi, Haider H., et al.
Publicado: (2018)

Second‐line treatment of hepatocellular carcinoma after sorafenib: Characterizing treatments used over the past 10 years and real‐world eligibility for cabozantinib, regorafenib, and ramucirumab
por: Fung, Andrea S., et al.
Publicado: (2020)

Continuous lenalidomide and low‐dose dexamethasone in patients with transplant‐ineligible newly diagnosed MM: FIRST trial subanalysis of Canadian/US patients
por: Belch, Andrew, et al.
Publicado: (2020)

Health-Related Quality of Life Outcomes With Two Different Starting Doses of Lenvatinib in Combination With Everolimus for Previously Treated Renal Cell Carcinoma
por: Bergerot, Cristiane, et al.
Publicado: (2023)

Population Pharmacokinetic Modelling and Simulation to Determine the Optimal Dose of Nanoparticulated Sorafenib to the Reference Sorafenib
por: Huh, Ki-Young, et al.
Publicado: (2021)

Phase II trial of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma after disease progression on sorafenib
por: El Dika, Imane, et al.
Publicado: (2020)

Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation
por: Groenendijk, Floris H, et al.
Publicado: (2015)

Assignment of Canadian Defined Daily Doses and Canadian Defined Course Doses for Quantification of Antimicrobial Usage in Cattle
por: Lardé, Hélène, et al.
Publicado: (2020)

Promising survival rate but high incidence of treatment‐related mortality after reduced‐dose craniospinal radiotherapy and tandem high‐dose chemotherapy in patients with high‐risk medulloblastoma
por: Lee, Ji Won, et al.
Publicado: (2020)

Impact of G-CSF Prophylaxis on Chemotherapy Dose-Intensity, Link Between Dose-Intensity and Survival in Patients with Metastatic Pancreatic Adenocarcinoma
por: Canton, Clémence, et al.
Publicado: (2022)

Dose escalation of radiotherapy in unresectable extrahepatic cholangiocarcinoma
por: Elganainy, Dalia, et al.
Publicado: (2018)

Sorafenib Induced Hand-Foot Skin Reaction at Low Dose
por: Shah, Vrutika H., et al.
Publicado: (2020)

Individualized Dose-Escalation of HDR Prostate Brachytherapy Implant to Decrease Required External Beam Radiation Dose: A Retrospective Feasibility Study
por: Dahn, Hannah M., et al.
Publicado: (2019)

Low-dose aspirin and risk of breast cancer: a Norwegian population-based cohort study of one million women
por: Løfling, Lukas, et al.
Publicado: (2023)

FAM225A promotes sorafenib resistance in hepatocarcinoma cells through modulating miR-130a-5p–CCNG1 interaction network
por: Liu, Yan-Tong, et al.
Publicado: (2020)

Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors
por: Berardi, Rossana, et al.
Publicado: (2017)

A Phase 2 Randomized Pilot Study Comparing High-Dose-Rate Brachytherapy and Low-Dose-Rate Brachytherapy as Monotherapy in Localized Prostate Cancer
por: Hathout, Lara, et al.
Publicado: (2019)

A real‐world, population‐based study of patterns of referral, treatment, and outcomes for advanced pancreatic cancer
por: Abdel‐Rahman, Omar, et al.
Publicado: (2018)

Improved survival prediction and comparison of prognostic models for patients with hepatocellular carcinoma treated with sorafenib
por: Labeur, Tim A., et al.
Publicado: (2019)

Soy intake and breast cancer risk: a prospective study of 300,000 Chinese women and a dose–response meta-analysis
por: Wei, Yuxia, et al.
Publicado: (2019)

Clinical Impact of Vitamin K Dosing on Sorafenib Treatment for Hepatocellular Carcinoma
por: Haruna, Yoshimichi, et al.
Publicado: (2017)

Acne Inversa-like Lesions Induced by a Low Dose of Sorafenib
por: Aubán-Pariente, Javier, et al.
Publicado: (2021)

Low circulating 25-hydroxyvitamin D level is associated with increased colorectal cancer mortality: a systematic review and dose–response meta-analysis
por: Wu, Guanghai, et al.
Publicado: (2020)

High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma
por: Wang, Xiaoen, et al.
Publicado: (2011)

Delivered dose can be a better predictor of rectal toxicity than planned dose in prostate radiotherapy
por: Shelley, L.E.A., et al.
Publicado: (2017)

Sestrin 2 confers primary resistance to sorafenib by simultaneously activating AKT and AMPK in hepatocellular carcinoma
por: Dai, Jimin, et al.
Publicado: (2018)

Dosing targeted and cytotoxic two‐drug combinations: Lessons learned from analysis of 24,326 patients reported 2010 through 2013
por: Nikanjam, Mina, et al.
Publicado: (2016)

Discussions about reproductive and sexual health among young adult survivors of cancer
por: Wang, Ying, et al.
Publicado: (2016)

Compliance with adjuvant capecitabine in patients with stage II and III colon cancer: comparison of administrative versus medical record data
por: Amlani, Adam, et al.
Publicado: (2016)

Transitioning From a Low-Dose-Rate to a High-Dose-Rate Prostate Brachytherapy Program: Comparing Initial Dosimetry and Improving Workflow Efficiency Through Targeted Interventions
por: Solanki, Abhishek A., et al.
Publicado: (2018)

High impact of macroaggregated albumin‐based tumour dose on response and overall survival in hepatocellular carcinoma patients treated with (90)Y‐loaded glass microsphere radioembolization
por: Garin, Etienne, et al.
Publicado: (2016)

Do androgen deprivation and the biologically equivalent dose matter in low‐dose‐rate brachytherapy for intermediate‐risk prostate cancer?
por: Tabata, Ryuji, et al.
Publicado: (2016)

The out-of-field dose in radiation therapy induces delayed tumorigenesis by senescence evasion
por: Goy, Erwan, et al.
Publicado: (2022)

Oral desensitization to milk: how to choose the starting dose!
por: Mori, Francesca, et al.
Publicado: (2010)

Sorafenib treatment in children with relapsed and refractory neuroblastoma: an experience of four cases
por: Okada, Keiko, et al.
Publicado: (2016)

Mechanistic Modelling Identifies and Addresses the Risks of Empiric Concentration-Guided Sorafenib Dosing
por: Ruanglertboon, Warit, et al.
Publicado: (2021)

Combination of transcatheter arterial chemoembolization and interrupted dosing sorafenib improves patient survival in early–intermediate stage hepatocellular carcinoma: A post hoc analysis of the START trial
por: Lee, Teng-Yu, et al.
Publicado: (2017)

Low‐dose irradiated mesenchymal stromal cells break tumor defensive properties in vivo
por: Stefani, Francesca Romana, et al.
Publicado: (2018)

Evaluating the clinical trends and benefits of low‐dose computed tomography in lung cancer patients
por: Qiao, Edmund M., et al.
Publicado: (2021)

Phosphorylated ERK is a potential prognostic biomarker for Sorafenib response in hepatocellular carcinoma
por: Liang, Yuelong, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_87j23c1v9sejuetbb2imkmt43s